{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:32:01Z","timestamp":1793640721591,"version":"4.5.1"},"reference-count":26,"publisher":null,"issue":"2","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>\n                    <jats:italic>Aim<\/jats:italic>\n                    \u00a0 \u00a0To study the role of growth differentiation factor 15 (GDF-15) in the long-term prognosis for patients after uncomplicated myocardial infarction (MI).\n                    <jats:italic>Material and methods \u00a0<\/jats:italic>\n                    \u00a0This study included 118 MI patients aged &lt;70 years with and without ST-segment elevation on electrocardiogram (ECG). All patients underwent an examination that included ECG, echocardiography, Holter ECG monitoring, routine laboratory tests, and tests for plasma N-terminal pro-brain natriuretic peptide (NT-proBNT) and GDF-15. GDF-15 was measured by ELISA. The dynamics of patients was evaluated by interviews at 1, 3, 6, and 12 months. The endpoints were cardiovascular death and hospitalization for recurrent MI and\/or unstable angina.\u00a0\n                    <jats:italic>Results<\/jats:italic>\n                    \u00a0 \u00a0Median concentration of GDF-15 in MI patients was 2.07 (1.55; 2.73) ng\/ml. No significant dependence was found between GDF-15 concentration and age and gender, MI localization, smoking, body weight index, total cholesterol, and low-density lipoprotein cholesterol. During 12-month follow-up, 22.8\u200a% of patients were hospitalized for unstable angina or recurrent MI. In 89.6\u200a% of all cases of recurrent events, GDF-15 was \u22652.07 ng\/ml. For patients with GDF-15 in the upper quartile, the time dependence of recurrent MI was logarithmic. High concentrations of NT-proBNP in MI patients were also associated with increased risk of cardiovascular death and recurrent cardiovascular events [RR, 3.3 (95\u200a% CI, 1.87\u20135.96), \u0440=0.046].\n                    <jats:italic>Conclusion \u00a0<\/jats:italic>\n                    \u00a0A combination of GDF-15 and NT-proBNP at high concentrations significantly reflects an adverse prognosis for patients with uncomplicated MI within 12 months [RR, 5.4 (95\u200a% CI, 3.4\u20138.5), \u0440=0.004].\n                  <\/jats:p>","DOI":"10.18087\/cardio.2023.2.n2152","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T03:36:26Z","timestamp":1678160186000},"page":"40-45","source":"Crossref","is-referenced-by-count":3,"title":["The role of growth differentiation factor-15 in assessing the prognosis of patients after uncomplicated myocardial infarction"],"prefix":"10.68900","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4510-6197","authenticated-orcid":true,"given":"A. S.","family":"Galyavich","sequence":"first","affiliation":[{"name":"Kazan State Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-0593","authenticated-orcid":true,"given":"A. A.","family":"Sabirzyanova","sequence":"additional","affiliation":[{"name":"Kazan State Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7974-5894","authenticated-orcid":true,"given":"L. V.","family":"Baleeva","sequence":"additional","affiliation":[{"name":"Kazan State Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9580-3695","authenticated-orcid":true,"given":"Z. M.","family":"Galeeva","sequence":"additional","affiliation":[{"name":"Kazan State Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Kharisova E.Kh., Galyavich A.S., Galeeva Z.M., Baleeva L.V. Evaluation of long-term prognosis after myocardial infarction. Vrach. 2019;30(12):14\u20137. DOI: 10.29296\/25877305-2019-12-04","DOI":"10.29296\/25877305-2019-12-04"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Sabatine MS, Braunwald E. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Journal of the American College of Cardiology. 2021;77(22):2822\u201345. DOI: 10.1016\/j.jacc.2021.01.060","DOI":"10.1016\/j.jacc.2021.01.060"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Hung J, Roos A, Kadesj\u00f6 E, McAllister DA, Kimenai DM, Shah ASV et al. Performance of the GRACE 2.0 score in patients with type 1 and type 2 myocardial infarction. European Heart Journal. 2021;42(26):2552\u201361. DOI: 10.1093\/eurheartj\/ehaa375","DOI":"10.1093\/eurheartj\/ehaa375"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Harrington RA, Ohman EM. Risk Stratification Science Goes to a New Level. JAMA Cardiology. 2021;6(3):314\u20135. DOI: 10.1001\/jamacardio.2020.6325","DOI":"10.1001\/jamacardio.2020.6325"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Li JJ, Liu J, Lupino K, Liu X, Zhang L, Pei L. Growth Differentiation Factor 15 Maturation Requires Proteolytic Cleavage by PCSK3, -5, and -6. Molecular and Cellular Biology. 2018;38(21):e00249-18. DOI: 10.1128\/MCB.00249-18","DOI":"10.1128\/MCB.00249-18"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Azevedo PS, Polegato BF, Minicucci MF, Paiva SAR, Zornoff LAM. Cardiac Remodeling: Concepts, Clinical Impact, Pathophysiological Mechanisms and Pharmacologic Treatment. Arquivos Brasileiros de Cardiologia. 2016;106:62\u20139. DOI: 10.5935\/abc.20160005","DOI":"10.5935\/abc.20160005"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Wehman B, Sharma S, Pietris N, Mishra R, Siddiqui OT, Bigham G et al. Mesenchymal stem cells preserve neonatal right ventricular function in a porcine model of pressure overload. American Journal of Physiology-Heart and Circulatory Physiology. 2016;310(11):H1816\u201326. DOI: 10.1152\/ajpheart.00955.2015","DOI":"10.1152\/ajpheart.00955.2015"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Wesseling M, Poel JHC, Jager SCA. Growth differentiation factor 15 in adverse cardiac remodelling: from biomarker to causal player. ESC Heart Failure. 2020;7(4):1488\u2013501. DOI: 10.1002\/ehf2.12728","DOI":"10.1002\/ehf2.12728"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Dominguez-Rodriguez A, Abreu-Gonzalez P, Hernandez-Baldomero IF, Avanzas P, Bosa-Ojeda F. Change in Growth Differentiation Factor 15, but Not C-Reactive Protein, Independently Predicts Major Cardiac Events in Patients with Non-ST Elevation Acute Coronary Syndrome. Mediators of Inflammation. 2014;2014:929536. DOI: 10.1155\/2014\/929536","DOI":"10.1155\/2014\/929536"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Zelniker TA, Jarolim P, Silverman MG, Bohula EA, Park J-G, Bonaca MP et al. Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTE-ACS. Clinical Chemistry and Laboratory Medicine. 2019;57(7):1084\u201392. DOI: 10.1515\/cclm-2018-1081","DOI":"10.1515\/cclm-2018-1081"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Hagstr\u00f6m E, James SK, Bertilsson M, Becker RC, Himmelmann A, Husted S et al. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. European Heart Journal. 2016;37(16):1325\u201333. DOI: 10.1093\/eurheartj\/ehv491","DOI":"10.1093\/eurheartj\/ehv491"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Adela R, Banerjee SK. GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective. Journal of Diabetes Research. 2015;2015:490842. DOI: 10.1155\/2015\/490842","DOI":"10.1155\/2015\/490842"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Kim Y-I, Shin H-W, Chun Y-S, Park J-W. CST3 and GDF15 ameliorate renal fibrosis by inhibiting fibroblast growth and activation. Biochemical and Biophysical Research Communications. 2018;500(2):288\u201395. DOI: 10.1016\/j.bbrc.2018.04.061","DOI":"10.1016\/j.bbrc.2018.04.061"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Emmerson PJ, Wang F, Du Y, Liu Q, Pickard RT, Gonciarz MD et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nature Medicine. 2017;23(10):1215\u20139. DOI: 10.1038\/nm.4393","DOI":"10.1038\/nm.4393"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Hagstr\u00f6m E, Held C, Stewart RAH, Aylward PE, Budaj A, Cannon CP et al. Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. Clinical Chemistry. 2017;63(1):325\u201333. DOI: 10.1373\/clinchem.2016.260570","DOI":"10.1373\/clinchem.2016.260570"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Yang L, Chang C-C, Sun Z, Madsen D, Zhu H, Padkj\u00e6r SB et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nature Medicine. 2017;23(10):1158\u201366. DOI: 10.1038\/nm.4394","DOI":"10.1038\/nm.4394"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Li J, Cui Y, Huang A, Li Q, Jia W, Liu K et al. Additional Diagnostic Value of Growth Differentiation Factor-15 (GDF-15) to N-Terminal B-Type Natriuretic Peptide (NT-proBNP) in Patients with Different Stages of Heart Failure. Medical Science Monitor. 2018;24:4992\u20139. DOI: 10.12659\/MSM.910671","DOI":"10.12659\/MSM.910671"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Kou H, Jin X, Gao D, Ma R, Dong X, Wei J et al. Association between growth differentiation factor 15 and left ventricular hypertrophy in hypertensive patients and healthy adults. Clinical and Experimental Hypertension. 2018;40(1):8\u201315. DOI: 10.1080\/10641963.2016.1273948","DOI":"10.1080\/10641963.2016.1273948"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Lew J, Sanghavi M, Ayers CR, McGuire DK, Omland T, Atzler D et al. Sex-Based Differences in Cardiometabolic Biomarkers. Circulation. 2017;135(6):544\u201355. DOI: 10.1161\/CIRCULATIONAHA.116.023005","DOI":"10.1161\/CIRCULATIONAHA.116.023005"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Dallmeier D, Brenner H, Mons U, Rottbauer W, Koenig W, Rothenbacher D. Growth Differentiation Factor 15, Its 12-Month Relative Change, and Risk of Cardiovascular Events and Total Mortality in Patients with Stable Coronary Heart Disease: 10-Year Follow-up of the KAROLA Study. Clinical Chemistry. 2016;62(7):982\u201392. DOI: 10.1373\/clinchem.2016.254755","DOI":"10.1373\/clinchem.2016.254755"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Schopfer DW, Ku IA, Regan M, Whooley MA. Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study). American Heart Journal. 2014;167(2):186-192.e1. DOI: 10.1016\/j.ahj.2013.09.013","DOI":"10.1016\/j.ahj.2013.09.013"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Gaggin HK, Szymonifka J, Bhardwaj A, Belcher A, De Berardinis B, Motiwala S et al. Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15, and Highly-Sensitive Troponin T Measurements in Patients With Chronic Heart Failure. JACC: Heart Failure. 2014;2(1):65\u201372. DOI: 10.1016\/j.jchf.2013.10.005","DOI":"10.1016\/j.jchf.2013.10.005"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Sabirzyanova A.A., Galyavich A.S., Baleeva L.V., Galeeva Z.M. Predictive value of growth differentiation factor-15 in patients with myocardial infarction. Russian Journal of Cardiology. 2021;26(2):28\u201333. DOI: 10.15829\/1560-4071-2021-4288","DOI":"10.15829\/1560-4071-2021-4288"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Wollert KC, Kempf T, Wallentin L. Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. Clinical Chemistry. 2017;63(1):140\u201351. DOI: 10.1373\/clinchem.2016.255174","DOI":"10.1373\/clinchem.2016.255174"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Wallentin L, Lindb\u00e4ck J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD et al. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. European Heart Journal. 2020;41(41):4037\u201346. DOI: 10.1093\/eurheartj\/ehaa697","DOI":"10.1093\/eurheartj\/ehaa697"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Damman P, Kempf T, Windhausen F, van Straalen JP, Guba-Quint A, Fischer J et al. Growth-differentiation factor 15 for long-term prognostication in patients with non-ST-elevation acute coronary syndrome: An Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. International Journal of Cardiology. 2014;172(2):356\u201363. DOI: 10.1016\/j.ijcard.2014.01.025","DOI":"10.1016\/j.ijcard.2014.01.025"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/2152\/1344","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:16:51Z","timestamp":1793639811000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/2152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,28]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2023.2.n2152","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,28]]}}}